Zydus Lifesciences Limited has informed the Exchange about General Updates

Listed Co AcquisitionStrategic Transactions View source PDF Explain this filing

ZYDUSLIFE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.1%Reaction day

₹983.00

prior close

₹981.00

announcement price

After-mkt

timing

Nifty 100market · index membership as recorded later (tracked since Jun 2026)+0.8%+0.3% vs market

Pharmaceuticals peers, median of 152sector+1.0%+0.1% vs sector

On the reaction day the stock moved 0.3 pts more than Nifty 100 and 0.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+1.1

10m

+0.9

15m

+1.2

30m

+1.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.1+0.8+0.3+1.0+0.1

Next day

+0.6+1.1-0.5+1.4-0.8

+1.1+1.8-0.6+1.3-0.2

+0.4+1.9-1.5+0.8-0.4

-0.1+1.5-1.7+0.3-0.4

+0.9+2.1-1.2+0.6+0.3

+1.2+2.3-1.1+0.9+0.3

15d

+2.2+4.4-2.2+0.6+1.6

+0.0+4.5-4.5+2.2-2.2

-5.0+5.6-10.6-2.5-2.5

-6.9+5.6-12.5-3.8-3.1

UpDownMarket · Nifty 100Sector · Pharmaceuticals peers, median of 152Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Zydus Lifesciences is acquiring the API (Active Pharmaceutical Ingredients) business of Sterling Biotech Limited (SBL) under a Business Transfer Agreement signed in September 2024. The closing date, originally set for December 31, 2024, was earlier extended to September 30, 2025. SBL is still working on completing certain conditions precedent, so both parties have signed another extension letter pushing the deadline to December 31, 2025. The transaction is now expected to close on or before that date.

Likely market impact

The deal is progressing but delayed, which is mildly negative as it signals slow execution; however, both parties remain committed and the extension is procedural, so no material impact on shareholders is expected unless the deal is called off later.